Agenda

Friday 28 October

08.45 Welcome and introductions 
MJ Keating
University of Texas MD Anderson Cancer Center, Houston TX, USA

Session 1 – Molecular biology

Chaired by H Dohner (Universitätsklinikum Ulm, Ulm, Germany) 

09.00 Perspectives and state of the art 
S Stilgenbauer
Universitätsklinikum Ulm, Ulm, Germany

09.30 Looking to the future with functional genomics 
C Croce
The Ohio State University, Columbus, OH, USA

10.00 Selected oral presentations from submitted abstracts

  • The significance of deletion architecture, ATM mutational status and genomic complexity in 11q deleted CLL
  • MiR-181a/b significantly enhance drug sensitivity of CLL cells via targeting multiple anti-apoptosis genes
  • MicroRNA mutational analysis in patients with CLL
  • Transcriptome sequencing reveals novel mutations and differential gene expression in stereotyped subsets of CLL

10.40 Discussion 

11.00-11.30 Coffee 

Session 2 – Cellular biology

Chaired by F Caligaris-Cappio (Instituto Scientifico San Raffaele, Milan, Italy)

11.30 The microenvironment 
F Cymbalista 
Hospital Avicenne, Bobigny, France

12.30 Clinical potential and ‘logical synergies’ 
JA Burger 
University of Texas MD Anderson Cancer Center, Houston TX, USA

12.30 Selected oral presentations from submitted abstracts

  • The irf4 gene, a susceptibility locus for CLL, controls establishment of follicular and marginal zone B-cell compartments in mice
  • Controlled depletion of autologous T cells facilitates a lasting CLL proliferation in the CLL xenograft model
  • Hs1 protein defines a distinct signaling pathway and influences the cell homing and migratory capacity in CLL primary cell

13.00 Discussion 

13.30 Lunch 

Session 3 – Prognostication

Chaired by N Kay (Mayo Clinic, Rochester, MN, USA)

15.00 State of the art and perspectives
W Wierda
University of Texas MD Anderson Cancer Center, Houston TX, USA

15.30 Selected oral presentations from submitted abstracts

  • Update on the international standardized approach for flow cytometric residual disease monitoring in CLL
  • The clinical significant of NOTCH and MYD88 mutations in patients enrolled onto the UK CLL4 treatment trial and in an early stage A CLL cohort.
  • Matba: a targeted oligonucleotide array for the assessment of genomic copy number alterations for risk stratification CLL

16.00 Discussion

16.45–18.00 Poster viewing

17.30–19.00 Welcome reception

Saturday 29 October

Session 4 – Treatment including SCT

Chaired by E Montserrat (Hospital Clinic – University of Barcelona, Barcelona, Spain)

09.00 State of the art and perspectives 
M Hallek
Universität zu Köln, Köln, Germany

09.30 Selected oral presentations from submitted abstracts

  • Interest of early determination of bone marrow MRD by a sensitive 6-color flow cytometry in the evaluation of response: the experience of the CLL2007FMP, an intergroup phase III randomized multicentric trial comparing fludarabine cyclophosphamide and rituximab versus FC and mabcampath in previously untreated CLL patients
  • The safety and tolerability of oral fludarabine, plus or minus oral cyclophosphamide and intravenous rituximab therapy in previously untreated patients with CLL aged greater than or equal to 65 years
  • Low-dose fludarabine and cyclophosphamide combined with rituximab is a safe and effective treatment option for elderly/comorbid patients with CLL/SLL
  • The impact of specific mutations in TP53 gene on the results of alemtuzumab therapy in CLL patients

10.15 Discussion 

11.00 Coffee

Session 4 Continued – Treatment including SCT

Chaired by E Montserrat (Hospital Clinic – University of Barcelona, Barcelona, Spain)

11.30 Transplantation 
D Maloney 
Fred Hutchinson Cancer Research Center, Seattle, WA, USA

12.00 Selected oral presentations from submitted abstracts

  • Feasibility analysis of nonmyeloabltive allogeneic stem cell transplantation in patients with CLL and 17p- deletion
  • FCR vs autologous stem cell transplantation as first-line treatment for CLL: A comparison of two prospective studies of the GCLLSG

12.30 Discussion

13.00–14.30 Lunch

Session 5 – Novel treatment approaches

Chaired by J Gribben (St Bartholomew’s and Royal London School of Medicine, London, UK)

14.30 Pipeline overview and perspectives
J Byrd
The Ohio State University, Columbus, OH, USA

15.00 ‘Logical synergies’ 
T Kipps 
University of California San Diego, San Diego, CA, USA

 

15.30 Selected oral presentations from submitted abstracts

  • The anti-tumor reactivity of ROR1-CAR modified T cells depends on the targeted epitope, CAR-affinity and design of the CAR extracellular domain
  • Phase-II study of Navitoclax (ABT-263) safety and efficacy in patients with relapsed or refractory CLL: interim results
  • BtK inhibitor, PCI-32765, delays CLL progression in a TCL1 adoptive transfer model by impairing migration and cell proliferation
  • Patterns of nodal response and lymphocytosis in patients with previously treated CLL receiving the selective phosphatidylinositol 3 kinase-delta inhibitor, CAL-101 (GS-1101) alone or in combination with rituximab

16.30 Discussion 

17.00-18.00 Poster viewing

Sunday 30 October

Session 6. Optimizing trial design in CLL

Chaired by S O’Brien (University of Texas MD Anderson Cancer Center, Houston TX, USA)

08.30 MRD and 17p- 
P Hillmen 
St James University Hospital, Leeds, UK

09.00 Future directions of clinical trials 
J Gribben 
St Bartholomew’s and Royal London School of Medicine, London, UK

09.30 Mechanism based strategies 
W Plunkett 
University of Texas MD Anderson Cancer Center, Houston TX, USA

10.00 Discussion

11.00–11.30 Coffee

Session 7. Perspectives from the iwCLL Scientific Committee

Chaired by MJ Keating (University of Texas MD Anderson Cancer Center, Houston TX, USA)

11.30 Case studies highlighting key topics and discussions 
S O’Brien
University of Texas MD Anderson Cancer Center, Houston TX, USA

11.50 Meeting highlights (including best poster award) 
P Ghia 
Università Vita-Salute San Raffaele, Milan, Italy

12.10 Review and discussion 
iwCLL Scientific Committee

12.30 Next steps for the iwCLL 
MJ Keating

13.00 Meeting close 

Click here to download a copy of the Agenda